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ABSTRACT
Type 2 diabetes mellitus (T2DM) affects millions
of people worldwide, elevating their risk of
developing a range of complications, including
chronic kidney disease (CKD). People with
T2DM and CKD (i.e., diabetic kidney disease,
DKD) have an increased risk of progressing to
end-stage kidney disease (ESKD), experiencing
cardiovascular complications, and premature
death. Despite this, DKD is primarily addressed
through management of risk factors, and there
are few pharmaceutical treatments capable of
reversing or delaying disease progression.
Canagliflozin is a sodium glucose co-trans-
porter 2 inhibitor that was initially developed as
a blood glucose–lowering agent for people with
T2DM. Evidence from clinical trials of canagli-
flozin in people with T2DM, as well as evidence
from cardiovascular outcomes trials in people
with T2DM and high cardiovascular risk, pro-
vided preliminary evidence suggesting that it
may also have beneficial renal effects. The
Canagliflozin and Renal Events in Diabetes with
Established Nephropathy Clinical Evaluation
(CREDENCE) trial was a dedicated renal out-
comes trial of canagliflozin that assessed its
renal effects in people with DKD. Overall, the
CREDENCE trial demonstrated that canagli-
flozin improves renal outcomes and slows early
disease progression in people with DKD. These
data supported the approval of canagliflozin for
the treatment DKD, the first new treatment in
almost 20 years; therefore, it is important for
clinicians to understand how to implement this
treatment in their clinical practice.
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Key Summary Points
People with type 2 diabetes have a high
risk of developing diabetic kidney disease
(DKD), which is the leading cause of end-
stage kidney disease
There are few pharmaceutical treatments
capable of reversing or delaying the
progression of DKD
The Canagliflozin and Renal Events in
Diabetes with Established Nephropathy
Clinical Evaluation (CREDENCE) trial was
a dedicated renal outcomes trial of the
sodium glucose co-transporter 2 inhibitor
canagliflozin in people with DKD
Results from CREDENCE demonstrated
that canagliflozin improves renal
outcomes and slows early disease
progression in people with DKD
This article reviews the key results from
CREDENCE, along with context and
guidance for clinicians on how to
implement canagliflozin treatment in
their clinical practice
DIABETIC KIDNEY DISEASE:
BURDEN AND TREATMENT
More than 34 million Americans have diabetes,
and over 90% have type 2 diabetes mellitus
(T2DM) [1, 2]. People with T2DM are at high
risk of developing microvascular and
macrovascular complications such as chronic
kidney disease (CKD), which affects approxi-
mately 40% of people with T2DM and is the
leading cause of end-stage kidney disease
(ESKD) globally and in the USA [3–7]. CKD
represents a variety of kidney-related diseases
that are not necessarily related to T2DM; how-
ever, kidney disease that is pathologically rela-
ted to T2DM can be classified as diabetic kidney
disease (DKD). Clinically, DKD is identified by
persistent urinary albumin to creatinine ratio
(UACR) C 30 mg/g and/or sustained estimated
glomerular filtration rate (eGFR)\ 60 mL/min/
1.73 m2 [8]. People diagnosed with DKD will
experience continued reductions in eGFR,
increased albuminuria, and glomerular hyper-
filtration, all of which increase their cardiovas-
cular risk [9–13]. DKD increases the rate of
10-year cumulative all-cause mortality in people
with T2DM by almost 20%, with the majority of
this residual risk attributed to death from car-
diovascular complications [8, 14]. Heart failure
is the most common cardiovascular complica-
tion among people with DKD, and the risk of
developing heart failure is 2.5 times higher for
people with T2DM compared to non-diabetic
individuals, with this risk increasing with
decreasing eGFR [15]. Osteoporosis, fracture,
retinopathy, neuropathy, and amputation are
also complications commonly seen in people
with DKD [16–20].
Despite the risks associated with DKD,
awareness of kidney disease is low among peo-
ple with T2DM, particularly at early stages when
the disease is generally asymptomatic; just
40–50% of people with stage 4 or 5 CKD are
aware of their condition (Fig. 1) [21, 22]. The
prevalence and major life-threatening risks
associated with CKD make this condition costly
for the health care system. In 2016, approxi-
mately 20% of overall Medicare expenditures
were attributed to CKD (excluding ESKD), and
more than 40% of Medicare spending in people
with diabetes was allocated to the management
of CKD [23]. The substantial impact of kidney
disease led the US Department of Health and
Human Services to announce its Advancing
American Kidney Health initiative, which has a
goal of reducing the number of Americans
developing ESKD by 25% by 2020 [24].
Currently, the recommended approach to
slow the progression of DKD is management of
underlying risk factors, including hypertension,
hypoxemia, hyperglycemia, albuminuria, and
increased adiposity, along with refraining from
smoking and following a low-protein diet
[9, 25–28]. Beyond this, people have few treat-
ment options, and little progress has been made
in this area over the past two decades, which
has left a substantial proportion of people with
DKD at high risk for progression to renal failure,
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cardiovascular morbidity, and cardiovascular
mortality.
Renin–angiotensin–aldosterone system
(RAAS) inhibitors, such as angiotensin-convert-
ing enzyme (ACE) inhibitors and/or angiotensin
receptor blockers (ARBs), are recommended for
the management of hypertension and heart
failure [29–31]. Evidence from clinical trials in
people with T2DM suggested that RAAS inhibi-
tors may provide renal benefits in this popula-
tion; however, only two ARBs (losartan and
irbesartan) and no ACE inhibitors are approved
for the prevention of kidney function decline in
people with T2DM and albuminuria
([300 mg/g) [29, 30, 32–35]. Additionally,
RAAS inhibitors have been associated with
safety risks such as hyperkalemia and acute
kidney injury [9, 26]. Considering the current
state of treatment for DKD, new medications
capable of preventing or delaying the progres-
sion of this disease are needed.
Recent studies have investigated the poten-
tial renal benefits associated with sodium glu-
cose co-transporter 2 (SGLT2) inhibitors, which
were first developed and approved for the
management of hyperglycemia in people with
T2DM [36–38]. Unlike other classes of antihy-
perglycemic agents (AHAs), SGLT2 inhibitors
work independently of insulin by lowering the
renal threshold for glucose excretion (RTG) in
people with T2DM, thereby increasing urinary
glucose excretion (UGE) and leading to a mild
osmotic diuresis and a net caloric loss that
contribute to improvements in glycemic con-
trol, weight loss, and blood pressure reduction
[39, 40]. SGLT2 inhibition has also been asso-
ciated with renal hemodynamic changes, such
as attenuation of renal hyperfiltration and nor-
malization of tubuloglomerular feedback,
which may contribute to renal benefits (Fig. 2)
[41].
Evidence from cardiovascular outcome trials
(CVOTs) of SGLT2 inhibitors in people with
T2DM and established cardiovascular disease or
cardiovascular risk provided evidence suggest-
ing that this class may also have beneficial renal
effects [42–44]. However, the patient popula-
tions enrolled in the CVOTs were generally at
low renal risk, with eGFR ranging from 60 to
\90 mL/min/1.73 m2 and UACR\30 mg/g. In
addition, the number of events accumulated
was not enough to definitively establish the
effects on renal outcomes [43]. For example, in
the CANagliflozin cardioVascular Assessment
Study (CANVAS) Program, which was the CVOT
for the SGLT2 inhibitor canagliflozin, partici-
pants had mean eGFR of 76.5 mL/min/1.73 m2,
median UACR of 12.3 mg/g, and 80.0% were
receiving a RAAS inhibitor [43]. CVOTs for
other SGLT2 inhibitors, including EMPA-REG
OUTCOME (empagliflozin) and DECLARE-
TIMI 58 (dapagliflozin), recruited a similar
population with low renal risk. As a result of
this population profile, the number of renal
outcomes accumulated in these trials was too
low to definitively determine the impact of
SGLT2 inhibitors on renal outcomes; there were
only 69 confirmed renal replacement therapy or
renal death events across the three studies,
which included more than 34,000 participants
[42–44]. Additionally, these studies were not
designed to specifically assess the impact of
intervention on renal endpoints, so all renal
studies were based on secondary, exploratory,
Fig. 1 Prevalence and awareness of CKD in adults with T2DM [11]. CKD chronic kidney disease, T2DM type 2 diabetes
mellitus
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or post hoc analyses. Thus, dedicated trials of
SGLT2 inhibitors in people with DKD were
necessary to assess the renal benefits afforded
through treatment of this population with this
class of medications. This article describes the
dedicated renal outcomes trial, Canagliflozin
and Renal Events in Diabetes with Established
Nephropathy Clinical Evaluation (CREDENCE),
which was the first study to demonstrate the
renal effects of canagliflozin in people with
T2DM and compromised kidney function (i.e.,
DKD) [45].
COMPLIANCE WITH ETHICS
GUIDELINES
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
CREDENCE STUDY DESIGN
CREDENCE was an event-driven trial designed
to formally test whether canagliflozin lowers
the risk of kidney failure and cardiovascular
outcomes in people with T2DM and established
diabetic nephropathy [45, 46]. The CREDENCE
trial was initiated in 2014 before the conclusion
of the CVOTs and its initiation was motivated
by renal data measured in phase 3 studies of
canagliflozin [45]. The study population inclu-
ded adults at least 30 years of age with T2DM
(HbA1c C 6.5% and B 12.0%), eGFR C 30 and
\90 mL/min/1.73 m2, and UACR[ 300 and
B 5000 mg/g [45, 46]. People were also required
to be receiving a maximally tolerated dose of an
ACE inhibitor or ARB for at least 4 weeks prior
to randomization [45, 46]. The CREDENCE trial
was stopped 2 years early on the advice of an
independent data monitoring committee on
the basis of the efficacy and safety findings
observed in an interim analysis conducted in
July 2018 after a planned 405 primary endpoint
events had occurred [46].
The primary endpoint of the CREDENCE
trial was the composite of ESKD (defined as the
need for chronic dialysis for 30 days or more,
kidney transplantation, or eGFR\ 15 mL/min/
1.73 m2 sustained for at least 30 days by central
laboratory assessment), doubling of serum
Fig. 2 Tubuloglomerular feedback mechanisms encoun-
tered under normal physiology, in the early stages of
diabetic nephropathy, and after SGLT2 inhibition [41].
SGLT2 sodium glucose co-transporter 2, TGF
tubuloglomerular feedback, GFR glomerular filtration rate.
Reproduced with permission from Cherney et al. [41]
1240 Diabetes Ther (2020) 11:1237–1250
creatinine, or renal or cardiovascular death
[45, 46]. Secondary endpoints were tested
according to a prespecified hierarchical testing
sequence as follows: cardiovascular death or
hospitalization for heart failure; cardiovascular
death, myocardial infarction, or stroke (i.e.,
3-point major adverse cardiovascular event,
MACE); hospitalization for heart failure; the
composite of ESKD, doubling of serum crea-
tinine, or renal death; cardiovascular death; all-
cause mortality; and the composite of cardio-
vascular death, myocardial infarction, stroke,
hospitalization for heart failure, or hospitaliza-
tion for unstable angina [45, 46]. All renal and
cardiovascular endpoints that were part of
planned primary and secondary composite
endpoints were adjudicated by a blinded end-
point adjudication committee [45, 46]. Other
outcomes of interest included the effects on
intermediate outcomes, including eGFR, UACR,
HbA1c, and blood pressure.
EFFICACY OUTCOMES
WITH CANAGLIFLOZIN
IN CREDENCE
A total of 4401 people were enrolled in the
CREDENCE trial and randomized (1:1) to cana-
gliflozin 100 mg or placebo. Participants had a
mean age of 63 years, HbA1c of 8.3%, body
mass index of 31.3 kg/m2, and had T2DM for an
average duration of 16 years. Most CREDENCE
trial participants were male (66%) and white
(67%) [46]. In addition, 60% of people had
eGFR\ 60 mL/min/1.73 m2 at baseline. Over-
all, participants had a mean eGFR of 56.2 mL/
min/1.73 m2, a median UACR of 927 mg/g, and
99.9% were taking a maximally tolerated dose
of a RAAS inhibitor.
Canagliflozin treatment was associated with
a 30% relative risk reduction of the primary
composite outcome of ESKD, doubling of serum
creatinine, or renal or cardiovascular death
compared with placebo (hazard ratio [HR], 0.70;
95% confidence interval [CI] 0.59–0.82;
P = 0.00001; Fig. 3) [46]. Consistent effects were
seen for the components of the primary com-
posite endpoint, as well as the secondary renal,
cardiovascular, and mortality endpoints (Fig. 4).
The effects of canagliflozin on reducing the
risk of the primary outcome were observed
consistently across participant subgroups,
including those defined by history of cardio-
vascular disease, screening eGFR, race, ethnic-
ity, and baseline HbA1c; effects were also
generally similar across subgroups for other
renal, cardiovascular, and mortality outcomes
[47–50]. Of note, canagliflozin was the first AHA
to demonstrate renal and cardiovascular bene-
fits in a population without cardiovascular dis-
ease history [50]. The renal and cardiovascular
effects of canagliflozin were also consistent
across eGFR subgroups, including in partici-
pants with screening eGFR of 30 to \45 mL/
min/1.73 m2 [48, 51]. A post hoc analysis in
participants with baseline eGFR\ 30 mL/min/
1.73 m2 (n = 174) also demonstrated consistent
effects of canagliflozin on renal, cardiovascular,
and mortality outcomes as those seen in the
overall population, with no differences in the
risk of renal-related adverse events or other
safety outcomes compared to the overall popu-
lation [46, 48].
As seen in previous studies, canagliflozin
treatment was associated with an acute drop in
eGFR from baseline to week 3 (Fig. 5) [46]. This
initial decline in eGFR was seen rapidly and
attenuated over time [52]. After this initial drop,
the rate of eGFR decline was reduced by
approximately 60% with canagliflozin com-
pared to placebo, suggesting that canagliflozin
treatment may help to delay progression of
renal function decline [46]. In addition, cana-
gliflozin was also associated with a 31% reduc-
tion in UACR compared with placebo over the
course of the trial.
The number needed to treat (NNT) has been
reported for key outcomes from the CREDENCE
trial (Fig. 6). The NNT to prevent one event
from the primary composite outcome was 22
(95% CI 15–38). NNTs for other outcomes were
28 (95% CI 19–54) for the composite renal
outcomes of ESKD, doubling of the serum cre-
atinine level, or renal death; 43 (95% CI
26–121) for ESKD events; and 46 (95% CI
29–124) for hospitalization for heart failure.
These findings further demonstrate the benefi-
cial effects of canagliflozin on renal and car-
diovascular outcomes in people with DKD.
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SAFETY OUTCOMES
WITH CANAGLIFLOZIN
IN CREDENCE
The overall safety profile of canagliflozin in the
CREDENCE trial was generally consistent with
the previous studies of canagliflozin (Fig. 7)
[46]. In CREDENCE, overall adverse events and
serious adverse events were lower among par-
ticipants receiving canagliflozin compared with
placebo. There was no difference between
canagliflozin and placebo for the incidence of
adverse events of interest, including malignan-
cies, urinary tract infections, volume depletion,
hypoglycemia, osmotic diuresis, and hypersen-
sitivity/cutaneous reactions [46]. Furthermore,
canagliflozin treatment resulted in a lower risk
of renal-related adverse events compared to
those treated with placebo (HR, 0.71; 95% CI
0.61–0.82) [46]. There was no difference
observed in the risk of acute kidney injury
between the participants receiving canagliflozin
and placebo (HR, 0.85; 95% CI 0.64–1.13) [46].
Notably, in CREDENCE there was no differ-
ence between canagliflozin and placebo in the
rates of amputation (HR, 1.11; 95% CI
0.79–1.56) or fracture (HR, 0.98; 95% CI
0.70–1.37) [46]. These results are in contrast
with the CANVAS Program, which found an
increased risk of amputation (HR, 1.97; 95% CI
1.41–2.75), and the CANVAS trial, which found
an increased risk of fracture (HR, 1.55; 95% CI
1.21–1.97) in participants treated with canagli-
flozin [43]. The reason for this discrepancy is
not known and, with the exception of an
increased risk of amputation observed in studies
of ertugliflozin, other clinical studies of SGLT2
inhibitors, including phase 3 trials of canagli-
flozin, have not shown this same risk
[44, 53–55].
CLINICAL PERSPECTIVE
DKD is a devastating disease that puts people
with T2DM at an increased risk for developing
several serious and life-threatening conditions.
The dearth of new treatments for DKD over the
Fig. 3 Primary composite outcome of ESKD, doubling of
serum creatinine, or renal or cardiovascular death in
CREDENCE [46]. ESKD end-stage kidney disease. From
Perkovic et al. [46]. Copyright  2020 Massachusetts
Medical Society. Reprinted with permission from Mas-
sachusetts Medical Society
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last two decades has presented a challenge for
disease management and created an immense
economic burden. The CREDENCE trial was
uniquely designed compared with previous tri-
als because of its focus on renal outcomes and
its study population, which included people
with DKD. Thus, CREDENCE was the first study
to provide definitive evidence demonstrating
the effects of canagliflozin in slowing kidney
function decline in this population with com-
promised kidney function. In addition to its
renal benefits, CREDENCE was the first study to
show the efficacy of an AHA for preventing
cardiovascular events in those without a history
of cardiovascular disease [46].
In addition to providing evidence for the
beneficial effects of canagliflozin in slowing
kidney function decline in people with DKD,
results from the CREDENCE trial demonstrated
a favorable safety profile that did not result in
an increased risk of amputation or fracture with
canagliflozin. It remains important for
clinicians to remember that good clinical prac-
tice and proper foot care are always crucial in
people with DKD, who are at an inherently
heightened baseline risk for amputation and
fracture.
The mechanism responsible for the renal
benefits associated with canagliflozin treatment
in the CREDENCE trial is unclear; however, a
number of potential hypotheses have been
generated. It has been proposed that the renal
benefits associated with SGLT2 inhibition are
achieved through a renal hemodynamic effect
that may attenuate renal hyperfiltration and
normalization of tubuloglomerular feedback by
blocking sodium reabsorption at renal proximal
tubules, ultimately increasing sodium delivery
to the macula densa [41, 56–59]. A number of
alternative mechanisms have been proposed
and are under investigation, including effects
on albuminuria; glucose-mediated inflamma-
tion, proliferation, and fibrosis; proximal tubule
hypertrophy; oxidative stress; and
Fig. 4 Effects of canagliflozin on cardiovascular and renal
outcomes in CREDENCE [46]. CI confidence interval,
eGFR estimated glomerular filtration rate, CV
cardiovascular. *The primary composite outcome included
end-stage kidney disease, doubling of serum creatinine, or
renal or CV death. This outcome was exploratory
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sodium–hydrogen exchanger expression
[60–64]. Furthermore, it has been hypothesized
that SGLT2 inhibitors complement the mecha-
nism of RAAS inhibition to improve renal and
cardiovascular outcomes in people receiving
ACE inhibitors and/or ARBs [65]. Indeed, the
renal benefits associated with canagliflozin
treatment were observed in addition to standard
Fig. 5 Effects of canagliflozin on eGFR slope over time
[46]. eGFR estimated glomerular filtration rate, LS least
squares, SE standard error, CI confidence interval. From
Perkovic et al. [46] Copyright  2020 Massachusetts
Medical Society. Reprinted with permission from Mas-
sachusetts Medical Society
Fig. 6 Number needed to treat to prevent one event from
the a primary composite outcome; b composite renal
outcomes of end-stage kidney disease, doubling of the
serum creatinine level, or renal death; c end-stage kidney
disease; d hospitalization for heart failure [46]. eGFR
estimated glomerular filtration rate. *ESKD (defined as the
need for chronic dialysis for at least 30 days, kidney
transplantation, or eGFR\ 15 mL/min/1.73 m2 sus-
tained for at least 30 days by central laboratory assess-
ment), doubling of serum creatinine, or renal or
cardiovascular death
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of care with RAAS inhibitors, which were being
taken by more than 99% of CREDENCE trial
participants. Future studies will be helpful to
decipher the mechanism responsible for the
renal benefits observed with canagliflozin,
which may help to inform future prescribing
recommendations related to the combined use
of SGLT2 inhibitors and RAAS inhibitors.
Renal outcomes data for people with DKD
are not yet available for other SGLT2 inhibitors;
however, trials for the SGLT2 inhibitors dapa-
gliflozin and empagliflozin that include this
population as well as people with CKD (without
T2DM) are ongoing and expected to be com-
pleted in late 2020 and 2022, respectively
[66, 67]. These data may help to clarify whether
the renal benefits seen with canagliflozin in
CREDENCE trial participants are a class effect of
SGLT2 inhibitors and whether these effects may
extend to people with CKD who do not have
T2DM to further establish the renal efficacy and
safety of this class of drugs.
The results from the CREDENCE trial
prompted the US Food and Drug Administra-
tion (FDA) to expand the indication for cana-
gliflozin to a new patient population [68]. Prior
to CREDENCE, canagliflozin was approved for
two indications: (1) as an adjunct to diet and
exercise to improve glycemic control in adults
with T2DM and (2) to reduce the risk of MACE
in adults with T2DM and established cardio-
vascular disease. On the basis of results from the
CREDENCE trial, the FDA approved canagli-
flozin to reduce the risk of ESKD, doubling of
serum creatinine, cardiovascular death, and
hospitalization for heart failure in adults with
Fig. 7 Effects of canagliflozin on safety outcomes in
CREDENCE [46]. CI confidence interval, AE adverse
event. *Includes male participants only (canagliflozin,
n = 1439; placebo, n = 1466). Includes female partici-
pants only (canagliflozin, n = 761; placebo, n = 731).
Includes malignant tumors of unspecified type
Diabetes Ther (2020) 11:1237–1250 1245
T2DM and diabetic nephropathy with albu-
minuria ([ 300 mg/day). The US prescribing
information for canagliflozin was also updated
to allow the continuation of canagliflozin
100 mg in people already receiving therapy
whose eGFR falls to\30 mL/min/1.73 m2 with
a UACR[300 mg/g until initiation of dialysis
or kidney transplantation [68]. Evidence from
the CREDENCE trial also prompted the Ameri-
can Diabetes Association to update its guideli-
nes in June 2019 to recommend that people
with T2DM with an eGFR C 30 mL/min/
1.73 m2 and albuminuria ([300 mg/g) consider
using an SGLT2 inhibitor to reduce their risk of
DKD progression and/or cardiovascular events
[69]. Further updates to these guidelines pub-
lished in 2020 suggested that SGLT2 inhibitors
should be considered independently of HbA1c
for people when atherosclerotic cardiovascular
disease, heart failure, or CKD predominates or
for people with T2DM and CKD who require
treatment in addition to metformin to attain
target HbA1c [70]. Taken together, these new
recommendations demonstrate that canagli-
flozin treatment is beneficial to a diverse array
of people in a broad range of circumstances, and
physicians should consider the unique charac-
teristics of each patient when determining if
canagliflozin is an appropriate treatment option
(Fig. 8).
CONCLUSION
The CREDENCE trial has demonstrated the
effects of canagliflozin that improve renal out-
comes and slow early disease progression in
people with T2DM and DKD. In addition to the
positive effects on kidney function, treatment
with canagliflozin also decreased the prevalence
of all comorbid complications in CREDENCE
trial participants, demonstrating the potential
this treatment has to reduce the DKD-related
expenditures in the health care industry. Data
from other trials investigating the use of SGLT2
Fig. 8 Updated dosing and eligibility guidelines for
canagliflozin [68]. eGFR estimated glomerular filtration
rate, CVD cardiovascular disease, UACR urinary albumin
to creatinine ratio, MACE major adverse cardiovascular
events, CV cardiovascular, HHF hospitalization for heart
failure. Note that ‘‘No restrictions’’ and ‘‘Some restrictions’’
refer to the eligibility requirements of patients for
treatment with canagliflozin based on the criteria specified
in each row/column. For those with ‘‘Some restrictions,’’
the specific thresholds are provided in the figure. *Varies
depending on specific goals of patient. Dose can be
increased to 300 mg for better glycemic control if
eGFR[ 60 mL/min/1.73 m2. Patient can continue
treatment with eGFR\ 30 mL/min/1.73 m2 as long as
UACR is[ 300 mg/g
1246 Diabetes Ther (2020) 11:1237–1250
inhibitors will be crucial for further establishing
the value and efficacy of this class of drugs in
people at high renal risk and probing the
extension of these benefits to a wider range of
people.
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